Please use this identifier to cite or link to this item:
https://doi.org/10.3390/cancers13174486
Title: | Targeting cd82/kai1 for precision therapeutics in surmounting metastatic potential in breast cancer | Authors: | Viera, Maximillian Yip, George Wai Cheong Shen, Han-Ming Baeg, Gyeong Hun Bay, Boon Huat |
Keywords: | CD82 mimics Epigenetic drugs Etoposide Metastasis suppressor Tetraspanins Tyrosine kinase inhibitors |
Issue Date: | 6-Sep-2021 | Publisher: | MDPI | Citation: | Viera, Maximillian, Yip, George Wai Cheong, Shen, Han-Ming, Baeg, Gyeong Hun, Bay, Boon Huat (2021-09-06). Targeting cd82/kai1 for precision therapeutics in surmounting metastatic potential in breast cancer. Cancers 13 (17) : 4486. ScholarBank@NUS Repository. https://doi.org/10.3390/cancers13174486 | Rights: | Attribution 4.0 International | Abstract: | Metastasis is the main cause of mortality in breast cancer patients. There is an unmet need to develop therapies that can impede metastatic spread. Precision oncology has shown great promise for the treatment of cancers, as the therapeutic approach is tailored to a specific group of patients who are likely to benefit from the treatment, rather than the traditional approach of “one size fits all”. CD82, also known as KAI1, a glycoprotein belonging to the tetraspanin family and an established metastasis suppressor, could potentially be exploited to hinder metastases in breast cancer. This review explores the prospect of targeting CD82 as an innovative therapeutic approach in precision medicine for breast cancer patients, with the goal of preventing cancer progression and metastasis. Such an approach would entail the selection of a subset of breast cancer patients with low levels of CD82, and instituting an appropriate treatment scheme tailored towards restoring the levels of CD82 in this group of patients. Proposed precision treatment regimens include current modalities of treating breast cancer, in combination with either clinically approved drugs that could restore the levels of CD82, CD82 peptide mimics or non-coding RNA-based therapeutics. © 2021 by the authors. Licensee MDPI, Basel, Switzerland. | Source Title: | Cancers | URI: | https://scholarbank.nus.edu.sg/handle/10635/233137 | ISSN: | 2072-6694 | DOI: | 10.3390/cancers13174486 | Rights: | Attribution 4.0 International |
Appears in Collections: | Staff Publications Elements |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_3390_cancers13174486.pdf | 1.42 MB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License